All News

lungs,art,red

Clinical Profile of RA-associated Interstitial Lung Disease

Jack Cush, MD

A prospective, cross-sectional analysis of patients with rheumatoid arthritis (RA) shows those with interstitial lung disease (ILD) tend to be older, obese and have a smoking history.

Read Article
epilepsy,brain,seizure,CVA

Antiphospholipid Antibodies With Incident Cardiovascular Events

Jack Cush, MD

Are antiphospholipid antibodies (aPL) associated with atherosclerotic cardiovascular (ASCVD) event risk?  A cohort study has shown that aPL Abs are found in a substantial proportion of adults with ASCVD events and finding both positive aCL IgA and aβ2GPI IgA Abs independently predicted futur

Read Article
warning, caution

EMA Final Update on JAK Inhibitors and MACE, Malignancy & VTE Risks

Jack Cush, MD

The EMA has updated recommendations regarding the use of JAK inhibitors by issuing a direct healthcare professional communication summarizing the data and warnings regarding an increased risk of malignancy, major adverse cardiovascular events (MACE), serious infections, VTE, and mortality in some patients receiving JAKi for the treatment of chronic inflammatory disorders.

Read Article
Lungs ILD

Tofacitinib May Reduce Interstitial Lung Disease Risk in RA

MedPage Today

Tofacitinib (Xeljanz) in patients with rheumatoid arthritis (RA) stood out among several other biologic and targeted synthetic disease-modifying antirheumatic drugs (sDMARDs) when it came to the incidence of interstitial lung disease (ILD), a retrospective cohort study showed.

Read Article
hospital-13-1518181.jpg

Higher Rehospitalization Rates in Younger SLE Patients

Jack Cush, MD

A Medicare study shows that young adults with systemic lupus erythematosus (SLE) exhibit very high 30-day rehospitalization rates (36%) that are significantly higher than older SLE patients and age matched non-SLE patients.

Read Article
pso.PsA_.NPF_.jpg

Does Biologic Treatment in Psoriasis Reduce the Risk of Psoriatic Arthritis?

Jack Cush, MD

Retrospective claims analysis shows that psoriasis patients treated with either an IL-12/23 inhibitor or an IL-23 inhibitor had a lower risk of developing incident psoriatic arthritis, compared to TNF inhibitors or IL-17 inhibitors.

Read Article
sclerodact.jpg

Long-Term Benefit of Rituximab in Systemic Sclerosis

Jack Cush, MD

A small cohort trial of rituximab (RTX) in 29 systemic sclerosis patients showed significantly improved skin sclerosis and lung function after a follow-up of 96 weeks.

Read Article
#RA with ILD portends poor outcomes, especially if seropositive. Visiting professor Dr. Jeff sparks @jeffsparks @UTSW_Rheum https://t.co/fbVyDMUm6L
Dr. John Cush RheumNow ( View Tweet)
Antiphospholipid Antibodies With Incident Cardiovascular Events Are antiphospholipid antibodies (aPL) associated with atherosclerotic cardiovascular (ASCVD) event risk? https://t.co/XQk17P6D2f https://t.co/y5exrsicW8

Links:

Dr. John Cush RheumNow ( View Tweet)
EMA Final Update on JAK Inhibitors and MACE, Malignancy & VTE Risks https://t.co/rMEqodKdVN https://t.co/OT0gRRADIc

Links:

Dr. John Cush RheumNow ( View Tweet)
Atopic Disease Increases Osteoarthritis Risk Analysis of commercial insurance claims suggests that patients with asthma or atopic dermatitis have a significantly increased risk of osteoarthritis (OA). https://t.co/450DnhOfY5 https://t.co/zUfD4jhumY

Links:

Dr. John Cush RheumNow ( View Tweet)
Tofacitinib May Reduce Interstitial Lung Disease Risk in RA Tofacitinib (Xeljanz) in patients with RA stood out among several other biologic and targeted sDMARDs when it came to the incidence of ILD, a retrospective cohort study showed. https://t.co/2DCn53Rk4z https://t.co/sZYhgfCU0E

Links:

Dr. John Cush RheumNow ( View Tweet)
Network metaanalysis of 7 dietary RCTs in high risk CV pts (40 RCTs, 35 548 pts), showed only Mediterranean (OR 0.72) & low fat (OR 0.84) diet reduce all cause mortality; Med-diet also reduced CV mortality (0.55), stroke (0.65) & non-fatal MI (0.48) https://t.co/ibUknLlwOx https://t.co/zRtvXObvg3

Links:

Dr. John Cush RheumNow ( View Tweet)
Tofacitinib May Reduce Interstitial Lung Disease Risk in RA Tofacitinib (Xeljanz) in patients with RA stood out among several other biologic and targeted sDMARDs when it came to the incidence of ILD, a retrospective cohort study showed. https://t.co/XKjuxLWAKH https://t.co/M7ri9AL2wH

Links:

Dr. John Cush RheumNow ( View Tweet)
Phase 3 trial of IV 200 mg qd hydrocortisone in 800 pts admitted to ICU for severe community-acquired pneumonia. Day 28 strongly favored IV Hydrocort vs PBO for mortality (6% v 12%; P=0.006), Mech ventilation (18% vs 29.5%), vasopressors (15% v 25%) https://t.co/TqxorRAuvc https://t.co/0R7kNaKgj5

Links:

Dr. John Cush RheumNow ( View Tweet)
Reassuring data by Dr. Laurent Arnaud on HCQ - arrhythmia risk from HCQ similar to general population @RheumNow #RNL2023 https://t.co/vMDg2SlbJQ
Robert B Chao, MD doctorRBC ( View Tweet)
@Lupusreference in #RNL2023 HCQ and arrhythmia via QTc prolongation At normal doses, same as general population If on other QTc prolonging medications, a baseline EKG may be beneficial @RheumNow https://t.co/cAN2vBNa1t
Eric Dein ericdeinmd ( View Tweet)
MTX lung disease: Presents at 6-12 months Baseline CXR is key to know if lung infiltrates are new #RNL2023 @RheumNow https://t.co/Whu4O1GLA9
Eric Dein ericdeinmd ( View Tweet)
28 biomarkers studied in 259 SSc-ILD, 179 SSc-NO ILD, 172 IPF & 30 healthy controls. Composite biomarker index (w/ SP-D [surfactant prot. D], Ca15-3 [MUC1], & ICAM-1) strongly correlated w/ SSc-ILD (adj OR 12.7); independent of age, sex, smoking, PFTs https://t.co/F0iKFqcZoY https://t.co/Ao25N1DFIx

Links:

Dr. John Cush RheumNow ( View Tweet)
Chest Pain & Fever Lessons from the clinic, brought to you by https://t.co/4UQlqwujiR March 18 &19, 2023 - Dallas, TX https://t.co/6iMT1Tt7KR https://t.co/owui66FMPJ

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×